What are the recommended drug treatments for pediatric molluscum contagiosum?

Drug Treatment for Pediatric Molluscum Contagiosum

For most pediatric patients with molluscum contagiosum, no drug therapy has proven highly successful, and the condition typically resolves spontaneously within 6-12 months; however, when treatment is indicated for cosmetically bothersome lesions or underlying skin conditions like eczema, 10% potassium hydroxide is the primary topical drug option, though physical modalities like cryotherapy remain equally effective. 1

Natural History and Treatment Rationale

• Molluscum contagiosum affects 5-11% of children aged 0-16 years and most commonly involves the trunk, face, and extremities 1
• Spontaneous resolution occurs in 6-12 months for uncomplicated cases, though complete clearance can take up to 4 years 1
• The condition is mostly asymptomatic but may present with pain, itching, redness, or bacterial superinfection 1

Evidence-Based Drug Treatments

Topical Potassium Hydroxide (Primary Drug Option)

• 10% potassium hydroxide has been used to treat lesions that are cosmetically bothersome or in patients with underlying eczema 1
• This treatment appears to have similar efficacy to cryotherapy in children 1

Imiquimod (NOT Recommended)

• Imiquimod was NOT shown to be of benefit compared with placebo in randomized controlled trials 1
• Despite this guideline-level evidence from 2017, some observational studies suggest potential benefit when used in personalized regimens 2, 3
• One 2003 open-label trial showed 69% response rate (9/13 children) with imiquimod 5% cream applied three times weekly for 16 weeks, though 23% discontinued due to local side effects 2
• A 2022 case-control study demonstrated complete clearance by week 20 in treated patients versus persistence in controls, but this contradicts the higher-quality randomized controlled trial evidence 3

Clinical caveat: The guideline evidence clearly states imiquimod failed in randomized controlled trials, making it an inappropriate first-line choice despite some positive observational data 1

Cantharidin (Limited Evidence)

• Open-label and observational studies indicate cantharidin can be effective, but one small randomized controlled trial of 29 patients showed improvement greater than placebo that was not statistically significant 1
• A 2018 prospective randomized trial (n=94) demonstrated that 36.2% in combined cantharidin arms achieved clearance versus 10.6% in placebo arms (P=0.0065), with good tolerability 4
• A 2009 retrospective study showed 96% improvement with average 2.2 treatments, though 46% experienced adverse events 5

Berdazimer Gel (Zelsuvmi) - FDA Approved 2024

• The FDA authorized Zelsuvmi (berdazimer sodium gel) on January 5,2024, as the first licensed prescription medication for molluscum contagiosum in patients over age 1 6
• Applied topically once daily for maximum 12 weeks 6
• Produces nitric oxide with antiviral properties through mechanisms affecting inflammation, immune control, and viral replication 6
• Most common adverse effects occur at application site: burning, itching, redness, and irritation 6
• Expected commercial availability in late 2024 6

Cidofovir (Immunocompromised Patients Only)

• Topical cidofovir 1% cream offers an effective alternative for recalcitrant molluscum in immunocompromised children 7
• A case series of 4 children (ages 5-8) with acute lymphoid leukemia showed lesion regression within 2-4 months, with complete regression in 3 patients by 7-9 months 7
• No side effects observed in this small series 7
• This should be reserved for immunocompromised patients where standard treatments fail 7

Treatment Algorithm

For immunocompetent children:

1. First-line: Observation for spontaneous resolution (6-12 months expected) if lesions are asymptomatic and not cosmetically concerning 1
2. Second-line: 10% potassium hydroxide OR cryotherapy with liquid nitrogen for cosmetically bothersome lesions or patients with eczema 1
3. Third-line: Consider berdazimer gel (Zelsuvmi) once commercially available, applied daily for up to 12 weeks 6
4. Avoid: Imiquimod (failed randomized controlled trials) 1

For immunocompromised children:

• Consider topical cidofovir 1% cream for recalcitrant cases after standard treatments fail 7
• Large and multiple molluscum lesions with little conjunctival inflammation may indicate immunocompromised state requiring further evaluation 8, 9, 8

Important Caveats

• Cryotherapy carries risk of postinflammatory hyperpigmentation or uncommonly scarring 1
• Treatment is primarily indicated for cosmetic concerns, underlying eczema, or to reduce transmission risk—not because the condition is medically dangerous 1
• In athletic settings, lesions should be covered to prevent transmission; specific return-to-competition guidelines exist 1
• The "watch and wait" approach increases risk of spreading virus to others and may cause psychosocial issues (anxiety, embarrassment, isolation) 10